MPE interviews experts about different aspects of the CARAMBA clinical trial
As part of the Horizon 2020 CARAMBA project, Myeloma Patients Europe (MPE) interviewed experts on different aspects of the CARAMBA clinical trial: manufacturing process, safety updates, and immune monitoring. The videos were filmed during the ASH annual meeting in December 2022. The CARAMBA project is a phase I/II clinical trial investigating innovative immunotherapy for treating myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide range of stakeholders, including MPE,…
ASH 2022 | Myeloma and AL amyloidosis updates
Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:
EHA 2022 highlights in myeloma and AL amyloidosis
The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, was held in Vienna, Austria from 9 June to 12 June 2022 in a hybrid format. Myeloma Patients Europe (MPE) attended EHA 2022 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting.
Watch the webinar “COVID-19 vaccines for myeloma patients: what you need to know.”
Myeloma Patients Europe (MPE) held the webinar “COVID-19 vaccines for myeloma patients: what you need to know” last Thursday, 29 April, to review the most recent updates on the approved COVID-19 vaccines in Europe and how they affect myeloma and AL amyloidosis patients.
Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights
Myeloma Patients Europe (MPE) held a webinar on ASH 2020 myeloma and AL amyloidosis highlights on 16 November to review the most recent myeloma research presented at the annual meeting of the American Society of Hematology (ASH) 2020 (5 – 8 December 2020).
ASH 2020 AL amyloidosis highlights
Myeloma Patients Europe interviewed Dr Giampaolo Merlini, the Research Director and AL amyloidosis expert from Policlinico San Matteo, University of Pavia, in Italy, to summarise the main highlights on this disease presented at the American Society of Hematology (ASH) Annual Meeting. Click to hear a summary of the most important studies presented at ASH 2020 and his views on the future of AL amyloidosis treatment.
ASH 2020 myeloma highlights
The largest haematology meeting in the calendar year, the American Society of Hematology (ASH) Annual Meeting, was held virtually from 5 to 8 December 2020.